eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.

Xisha ChenKuansong WangShilong JiangHongyin SunXuanling CheMinghui ZhangJiaying HeYing WenMengting LiaoXiangling LiXiaoming ZhouJianxun SongXingcong RenWenjun YiJinming YangXiang ChenMingzhu YinYan Cheng

Published in: Journal for immunotherapy of cancer (2022)

Our results suggest that eEF2K may serve as a biomarker for predicting therapeutic response and prognosis in patients receiving anti-PD-1 therapy, reveal a vital role of eEF2K in regulating TIME by controlling PD-L1 expression and provide a potential combination therapeutic strategy of eEF2K inhibition with ICB therapy.

Keyphrases

signaling pathway
genome wide
pi k akt
bone marrow
risk assessment
smoking cessation